Affiliation:
1. Department of Pharmacology, School of Basic Medical Sciences Capital Medical University Beijing China
2. Department of Gastrointestinal Surgery and Clinical Nutrition, Beijing Shijitan Hospital Captial Medical University Beijing China
3. Department of Pharmacy, Beijing Chaoyang Hospital Capital Medical University Beijing China
Abstract
AbstractAimsThe N‐methyl‐D‐aspartate (NMDA) receptor (NMDAR) has been proven to be strongly correlated with rapid antidepressant effects. Here, GW043, as a new compound targeting NMDAR, we explored its antidepressant effects and its mechanism of action.MethodsOur study utilized electrophysiological techniques to confirm the effect of GW043 on NMDAR currents. Additionally, we assessed the selectivity of GW043 through high‐throughput receptor‐ligand binding experiments. The antidepressant properties of GW043 were examined using rodent behavioral models including the Forced Swim Test (FST), Tail Suspension Test (TST), and Chronic Unpredictable Mild Stress (CUMS). Mechanistic insight into GW043's onset was gained through western blot analysis, BrdU staining, Golgi staining, and electrophysiological techniques.ResultsElectrophysiological studies indicated that GW043 acts as a partial agonist of NMDAR. Behavioral experiments confirmed the antidepressant effect of GW043 in rodents. Mechanistic investigations revealed that GW043 modulates synaptic plasticity through the LTP and BDNF‐mTOR pathways, consequently leading to an increase in the number of newborn neurons and subsequent antidepressant effects.ConclusionOur findings disclose that GW043, as a partial agonist of NMDAR, can reverse depression‐like behaviors in rats by modulating synaptic plasticity, indicating its potential as an antidepressant agent.
Funder
National Natural Science Foundation of China